龚珉 - 天津医科大学

个人简介

教育背景 1996年09月—2000年07月: 北京化工大学,生物化学, 学士 2001年01月—2005年01月: 曼彻斯特大学, 生物化学, 博士工作经历 2016年09月—今：天津医科大学，教授 2014年12月—2016年08月：牛津大学WIMM分子药物所，独立研究员 2011年01月—2014年12月：天津药物研究院，研究员 2008年12月—2011年12月：伯明翰大学，助理教授 2005年01月—2008年12月：牛津大学WIMM生物分子药物，博士后

研究领域

致力于创新生物分子药物的前期筛选、生物释药载体以及生物大分子口服载体的应用基础研究。

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

(1) Ying Li, Xuemin Zheng, Xiulin Yi, Changxiao Liu, Dexin Kong, Min Gong*. Myricetin, a small molecule of class B GPCRs receptor agonist, potent oral drug candidate for the treatment of type 2 diabetes. FASEB Journal. 2017, (E pub). (2) Wu Z, Zheng X, Gong M*, Li Y. Myricetin, a potent natural agent for treatment of diabetic skin damage by modulating TIMP/MMPs balance and oxidative stress. Oncotarget.2016 Sep 28. (3) Li Y, Zheng X, Gong M*, Zhang J. Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma.. Oncotarget. 2016 Oct 17 (4) Huang C, Yi X, Kong D, Chen L, Min G*. Controlled release stratgy of paclitaxel by conjugating to matrix metalloproteinses-2 sensitive peptide. Oncotarget. 2016 Jul 20. (5) Wang R, Zhang Q, Peng X, Zhou C, Zhong Y, Chen X, Qiu Y, Jin M, Gong M, Kong D. Stellettin B induces G1 arrest, apoptosis and autophagy in Human Non-small Cell Lung Cancer A549 cells via blocking PI3K/Akt/mTOR pathway. Sci Rep. 2016 May 31, 6: 27071. (6) Zhao L, Xu H, Li Y, Song D, Wang X, Qiao M, Gong M*. Novel application of hydrophobin in medical science: a drug carrier for improving serum stability. Sci Rep.2016 May 23, 6: 26461. (7) Li Y, Wang Y, Wei Q, Zheng X, Tang L, Kong D, Gong M*. Variant fatty acid-like molecules conjugation, novel approaches for extending the stability of therapeutic peptides. Sci Rep. 2015 Dec 11, 5: 18039. (8) Wu W, Dong Y, Gao J, Gong M, Zhang X, Kong W, Li Y, Zeng Y, Si D, Wei Z, Ci X, Jiang L, Li W, Li Q, Yi X, Liu C. aspartate-modified doxorubicin on its N-terminal increases drug accumulation in LAT1-overpressing tumors. Cancer Sci. 2015 Jun, 106(6):747-756. (9) Dan Hua, Xuemin Zheng, Weiling Kong, Changxiao Liu, Lida Tang, Ying Li and Min Gong*. A potent tumor targeting drug release system comprising MMP2 specific peptide fragment and self assembling feature. Drug Design, Development and Therapy. (10) Xue Yang, Ying Li, Xuemin Zheng, Weiling Kong, Changxiao Liu, Yazhuo Li and Min Gong*. Long-acting GLP-1 analog in V-shaped conformation by terminal poly-lysine modifications. Molecular Pharmaceutics. (11) Mu S, Liu Y, Gong M, Liu DK, Liu CX. Synthesis and biological evaluation of substituted desloratadines as potent arginine vasopressin V2 receptor antagonists. Molecules. 2014 Feb 24, 19(2):2694-2706. (12) Yazhuo Li, Lida Tang, Min Gong*. Development of Glucagon like peptide-1 (GLP-1) and preclinical studies for treatment of type 2 diabetes. Current Pharmaceutical Biotechnology. 2014, 14(9):835-841.